Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI
TAIPEI and SAN DIEGO, Sept. 18, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an Investigational New Drug (IND) application for Pidnarulex has been submitted to the U.S. FDA by the NCI....
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience’s Xafty by UCSD
SAN DIEGO, Sept. 18, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MOU with the University of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters, in treating "Long-COVID". The trial will be led by...
BioDuro-Sundia Appoints Dr. Armin Spura as New Chief Executive Officer
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the appointment of Dr. Armin Spura as its new Chief Executive Officer. Dr. Spura brings over two decades of experience in the life sciences and biotechnology sectors, with a proven track record of driving growth and innovation across global markets....
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced that clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors was presented at the...
Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) combined with bevacizumab in advanced colorectal cancer is...
USANA Ranked #1 Brand of Co-enzyme Q10 Sold Directly in Australia
CoQuinone 100 awarded by global market researcher Euromonitor International SYDNEY, Sept. 18, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. is proud to announce that its Australia market was recently recognized as the number one brand of Co-enzyme Q10 by market research giant Euromonitor International. This distinction is based on market research of...
MedAdvisor Solutions Launches Pharmacy Advisory Group to Empower and Expand the Role of the Pharmacist
Industry leaders collaborate to bring innovative approaches to evolving pharmacy needs CAMBERWELL, Australia, Sept. 18, 2024 /PRNewswire/ -- MedAdvisor Solutions, a global leader in pharmacy-driven patient engagement solutions, announced today the launch of its Pharmacy Advisory Group. The collaboration of industry experts will offer key insights to help MedAdvisor deliver solutions...
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
MELBOURNE, Australia, Sept. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET agent, Zircaix® (TLX250-CDx) for the imaging of kidney cancer in the...
Results Against All Odds: Education Cannot Wait Reaches 11 Million Children in Crises Worldwide
New ECW Results Report highlights significant learning outcomes achieved for children and adolescents in crisis settings and calls for urgent additional donor support to meet the rapidly escalating needs. NEW YORK, Sept. 18, 2024 /PRNewswire/ -- The global community is falling behind on its promise to ensure 'quality education for all' by 2030. Armed conflicts, forced displacement, climate...
Datasea’s New 5G AI Multimodal Agreements Have Already Generated $9.0 Million of 5G-AI Services
Agreements Boost Fiscal 2025 Revenue and Expand Datasea's 5G Application Market Positioning in China BEIJING, Sept. 17, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada-based company focused on innovative high-tech acoustics and 5G-Artificial Intelligence ("AI") multimodal digital technology in the United States and China, today announced that, on August 12, 2024, its Chinese...
